GlassScriptPhysician profile
Diptesh R Gupta
NPI 1326201260
$13,174.42
in general payments reported to CMS, 2019-2025
41 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,690 · 2020: $1,347 · 2021: $3,024 · 2022: $1,901 · 2023: $1,778 · 2024: $1,346 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,211 · Education: $1.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,211.13 |
| Education | $1.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $2,216.53 | 2019-2023 | Renal - Prismax System, Renal - Pd |
| Astrazeneca Pharmaceuticals LP | $1,849.10 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,493.87 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Bard Peripheral Vascular, INC. | $895.08 | 2019-2023 | Pristine |
| Daiichi Sankyo INC. | $751.14 | 2019-2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $616.44 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $485.41 | 2019-2023 | Veltassa |
| Opko Pharmaceuticals, LLC | $477.33 | 2019-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $451.04 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $403.47 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $357.92 | 2023-2025 | |
| Penumbra, INC. | $274.87 | 2023-2024 | Ruby Coil |
| Pharmacosmos Therapeutics INC. | $267.57 | 2021-2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.44 | 2023-2025 | Jardiance |
| Becton, Dickinson and Company | $215.64 | 2023-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diptesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.